1 month Will Non-COVID Drugs Again Boost Pfizer’s Top Line in Q3 Earnings?Zacks
Pfizer’s non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the third quarter.
Coronavirus · Earnings · Pfizer (PFE)
X